• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    10/18/24 4:47:58 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGTX alert in real time by email
    SC 13G/A 1 s13g_101524-meiragtx.htm SCHEDULE 13G/A

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. 2)1
     
     
    MeiraGTx Holdings plc
    (Name of Issuer)
     
     
    Ordinary Shares, $.00003881 par value
    (Title of Class of Securities)
     
    G59665102
    (CUSIP Number)
     
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [ ] Rule 13d-1(d)

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     
     

     

    CUSIP No. G59665102 Page 2

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

     

    Johnson & Johnson

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New Jersey

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 6,641,064
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 6,641,064
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,641,064
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.6%
    12. TYPE OF REPORTING PERSON CO
             

     

     

     

     
     

     

    CUSIP No. G59665102 Page 3

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

     

    Johnson & Johnson Innovation-JJDC, Inc.

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 6,641,064
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 6,641,064
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,641,064
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.6%
    12. TYPE OF REPORTING PERSON CO
             

     

     

     
     

     

    CUSIP No. G59665102 Page 4

     

     

    AMENDMENT NO. 2 TO SCHEDULE 13G

     

    Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Ordinary Shares of the Issuer on March 4, 2019 and Amendment No. 1 thereto on November 14, 2022 (as so amended, the “Schedule 13G”). Terms defined in the Schedule 13G are used herein as so defined.

     

    The following items of the Schedule 13G are amended and restated to read in their entirety as follows:

     

    Item 2(a). Name of Person Filing

     

    This statement is being filed by Johnson & Johnson, a New Jersey corporation (“J&J”), and Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation (“JJDC”) (together, the Reporting Persons”). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The Joint Filing Agreement between the Reporting Persons was filed as Exhibit 1 to the Schedule 13G.

     

    Item 2(a). Citizenship

     

    J&J: New Jersey

    JJDC: Delaware

     

    Item 4. Ownership

    The information requested in this item is incorporated herein by reference to the cover pages to this Amendment No. 2 to Schedule 13G. Ownership percentage is based on 77,184,187 Ordinary Shares outstanding as of August 13, 2024, as reported in the Issuer’s Prospectus on Form 424B5 filed with the Securities and Exchange Commission on of August 12, 2024 relating to an offering of Ordinary Shares that closed on August 13, 2024.

     

     
     

     

    CUSIP No. G59665102 Page 5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 18, 2024

     

     

    JOHNSON & JOHNSON

     

      By: /s/ Marc Larkins
      Name: Marc Larkins
      Title: Secretary
         
         
      JOHNSON & JOHNSON INNOVATION-JJDC, INC.
         
      By: /s/ Jill McManus
      Name: Jill McManus
      Title: Assistant Treasurer

     

     

     

    Get the next $MGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGTX

    DatePrice TargetRatingAnalyst
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & COO Giroux Richard sold $144,000 worth of Ordinary Shares (24,000 units at $6.00), decreasing direct ownership by 3% to 882,494 units (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/22/25 8:54:27 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT & CEO Forbes Alexandria sold $253,650 worth of Ordinary Shares (47,500 units at $5.34), decreasing direct ownership by 3% to 1,408,983 units (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/8/25 9:05:58 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO & COO Giroux Richard

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/7/25 9:05:31 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

      SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      11/12/24 9:40:33 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

      SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      10/18/24 4:47:58 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

      SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

      8/14/24 7:21:27 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plc

      SCHEDULE 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      5/14/25 8:30:35 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by MeiraGTx Holdings plc

      10-Q - MeiraGTx Holdings plc (0001735438) (Filer)

      5/13/25 8:09:19 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MeiraGTx Holdings plc (0001735438) (Filer)

      5/13/25 8:05:14 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

      LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2025, in New Orleans, LA. The posters will be available on the Posters and Publications page of the Company's website. The details of the poster presentations are below: Poster 507: An Ultra-Low Dose of a Localized CNS Gene Therapy for Severe Pediatric ObesityPoster Session: Tuesday, May 13, 6:00-7:30 pm CDTAbstract:Brain-derived neurotrophic factor (BDN

      5/13/25 4:30:00 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Reports First Quarter 2025 Financial and Operational Results

      -  Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson's disease -  Gained alignment with FDA on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential BL

      5/13/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

      -  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease -  RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the t

      5/9/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      8/14/24 6:54:38 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Financials

    Live finance-specific insights

    See more

    $MGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

      Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity, reaching the normal range in bilaterally treated participants by 2 months and persisting through the Month 12 assessmentAcross assessments, greater improvements observed in bilaterally treated participants compared to those treated unilaterally Early long-term follow-up data suggest durability of improvement to at least 3 years post-treatmentAAV2-hAQP1 appears safe and well tolerated at each dose te

      6/27/23 7:30:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023

      LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for

      6/22/23 4:01:00 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

      Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoin

      12/13/22 7:30:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

      Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

      7/31/24 6:30:53 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Landsdowne Labs Names Bryan Laulicht CEO

      Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

      6/13/23 9:05:00 AM ET
      $MGTX
      $AMAG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Pharmaceuticals
    • MeiraGTx Appoints Debra Yu, MD to Board of Directors

      LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen

      4/27/22 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care